ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,51
0,82%
Dow Jones
38 884,26
0,08%
DAX
18 514,26
0,41%
Brent Oil
81,805
-1,28%
Bitcoin
62 157,25
-0,26%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Amneal Pharmaceuticals Holding Co (AMRX)

  7. Amneal Pharmaceuticals Holding Co (AMRX) Actualités

AMRX

Amneal Pharmaceuticals (AMRX)

Amneal Pharmaceuticals Holding Co
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:AMRX
DateHeureSourceTitreSymboleSociété
07/05/202422h18Edgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
06/05/202423h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
03/05/202412h00Business WireAmneal Reports First Quarter 2024 Financial ResultsNYSE:AMRXAmneal Pharmaceuticals Holding Co
24/04/202414h00Business WireAmneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid OverdoseNYSE:AMRXAmneal Pharmaceuticals Holding Co
16/04/202414h00Business WireAmneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable MedicineNYSE:AMRXAmneal Pharmaceuticals Holding Co
10/04/202414h00Business WireAmneal to Report First Quarter 2024 Results on May 3, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
28/03/202421h05Business WireAmneal to Ring the Nasdaq Closing Bell on April 2, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
25/03/202421h05Business WireAmneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic SuspensionNYSE:AMRXAmneal Pharmaceuticals Holding Co
22/03/202413h01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNYSE:AMRXAmneal Pharmaceuticals Holding Co
22/03/202413h01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:AMRXAmneal Pharmaceuticals Holding Co
01/03/202412h00Business WireAmneal Reports Fourth Quarter and Full Year 2023 Financial ResultsNYSE:AMRXAmneal Pharmaceuticals Holding Co
27/02/202414h00Business WireAmneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203NYSE:AMRXAmneal Pharmaceuticals Holding Co
13/02/202414h00Business WireAmneal to Participate at Upcoming Investor ConferenceNYSE:AMRXAmneal Pharmaceuticals Holding Co
08/02/202422h05GlobeNewswire Inc.Amneal Announces Complete Response Resubmission for IPX203 New Drug ApplicationNYSE:AMRXAmneal Pharmaceuticals Holding Co
31/01/202422h05Business WireAmneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
10/01/202414h00Business WireAmneal Launches Complex Generic Fluorometholone Ophthalmic SuspensionNYSE:AMRXAmneal Pharmaceuticals Holding Co
04/01/202422h05Business WireAmneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023NYSE:AMRXAmneal Pharmaceuticals Holding Co
26/12/202322h10Edgar (US Regulatory)Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
26/12/202322h05Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NYSE:AMRXAmneal Pharmaceuticals Holding Co
21/12/202314h00Business WireAmneal to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:AMRXAmneal Pharmaceuticals Holding Co
15/12/202322h06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NYSE:AMRXAmneal Pharmaceuticals Holding Co
15/12/202322h05Business WireAmneal Announces Move to NasdaqNYSE:AMRXAmneal Pharmaceuticals Holding Co
07/12/202314h00Business WireAmneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)NYSE:AMRXAmneal Pharmaceuticals Holding Co
01/12/202322h15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NYSE:AMRXAmneal Pharmaceuticals Holding Co
01/12/202322h15Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NYSE:AMRXAmneal Pharmaceuticals Holding Co
01/12/202314h00Business WireAmneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel CapsulesNYSE:AMRXAmneal Pharmaceuticals Holding Co
20/11/202312h07Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NYSE:AMRXAmneal Pharmaceuticals Holding Co
15/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNYSE:AMRXAmneal Pharmaceuticals Holding Co
08/11/202323h15Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNYSE:AMRXAmneal Pharmaceuticals Holding Co
08/11/202323h13Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNYSE:AMRXAmneal Pharmaceuticals Holding Co
 Showing the most relevant articles for your search:NYSE:AMRX

Dernières Valeurs Consultées

NASDAQ
GOOGL
Alphabet
EU
EN
Bouygues
NYSE
MRK
Merck
EU
VIV
Vivendi
NYSE
JPM
JP Morgan Chase
EU
BEL20
Bel 20
EU
ML
Michelin
NASDAQ
AMZN
Amazon.com
EU
ORA
Orange
EU
DG
Vinci
EU
RI
Pernod Ricard
FTSE
UKX
FTSE 100
EU
VK
Vallourec
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés